The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday. reut.rs/4aaqEhr reut.rs/4aaqEhr
0
0
0
829
0